Literature DB >> 17822436

High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Emilie Lacombe1, Carole Carcenac, Sabrina Boulet, Claude Feuerstein, Anne Bertrand, Annie Poupard, Marc Savasta.   

Abstract

High-frequency stimulation of the subthalamic nucleus (STN-HFS) is a powerful approach for treating the motor symptoms of Parkinson's disease (PD). It results in clinical improvement in patients with PD, further reducing the l-3,4-dihydroxyphenylalanine (L-DOPA) requirement and thus L-DOPA-induced dyskinesia. However, it remains unclear how STN-HFS modifies the response to L-DOPA. We investigated the effect of STN-HFS on striatal extracellular concentrations of dopamine and its metabolites following acute L-DOPA administration in intact or partially dopaminergic denervated (DA-PL) rats. L-DOPA treatment significantly increased striatal dopamine levels in intact and DA-PL animals, with the maximal effect observed 1 h after L-DOPA injection. This increase was more pronounced in DA-PL rats (ipsilateral to the lesion) than in intact animals. It remained fairly stable 1 h after the maximal effect of L-DOPA and then decreased towards basal values. STN-HFS in intact rats had no effect on the maximal L-DOPA-induced increase in striatal extracellular dopamine concentration or the return to basal values, the profiles observed being similar to those for non-stimulated intact animals. Conversely, STN-HFS amplified the L-DOPA-induced increase in striatal dopamine levels during the stimulation period (1 h) in DA-PL rats and this increase was sustained throughout the post-stimulation period (2.5 h), without the return to basal levels observed in stimulated intact and non-stimulated rats. These new neurochemical data suggest that STN-HFS interferes with L-DOPA effects, probably synergically, by stabilizing dopamine levels in the striatum and shed light on the mechanisms of STN-HFS in PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822436      PMCID: PMC2798123          DOI: 10.1111/j.1460-9568.2007.05747.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  96 in total

Review 1.  Brain microdialysis studies on the control of dopamine release and metabolism in vivo.

Authors:  G W Arbuthnott; I S Fairbrother; S P Butcher
Journal:  J Neurosci Methods       Date:  1990-09       Impact factor: 2.390

2.  Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals.

Authors:  G L Snyder; R W Keller; M J Zigmond
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

3.  Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.

Authors:  L S Carman; F H Gage; C W Shults
Journal:  Brain Res       Date:  1991-07-12       Impact factor: 3.252

Review 4.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

Authors:  M J Zigmond; E D Abercrombie; T W Berger; A A Grace; E M Stricker
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

5.  The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons.

Authors:  J R Hollerman; A A Grace
Journal:  Brain Res       Date:  1990-11-19       Impact factor: 3.252

6.  Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats.

Authors:  E D Abercrombie; A E Bonatz; M J Zigmond
Journal:  Brain Res       Date:  1990-08-13       Impact factor: 3.252

7.  In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine.

Authors:  I S Fairbrother; G W Arbuthnott; J S Kelly; S P Butcher
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

8.  In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: I. Studies using veratrine and ouabain.

Authors:  I S Fairbrother; G W Arbuthnott; J S Kelly; S P Butcher
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

9.  Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study.

Authors:  P A Garris; R M Wightman
Journal:  J Neurosci       Date:  1994-01       Impact factor: 6.167

10.  Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

Authors:  J G Nutt; W R Woodward; J H Carter; S T Gancher
Journal:  Arch Neurol       Date:  1992-11
View more
  11 in total

Review 1.  Mechanisms and targets of deep brain stimulation in movement disorders.

Authors:  Matthew D Johnson; Svjetlana Miocinovic; Cameron C McIntyre; Jerrold L Vitek
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

2.  Axonal failure during high frequency stimulation of rat subthalamic nucleus.

Authors:  Fang Zheng; Katja Lammert; Barbara E Nixdorf-Bergweiler; Frank Steigerwald; Jens Volkmann; Christian Alzheimer
Journal:  J Physiol       Date:  2011-04-11       Impact factor: 5.182

Review 3.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

4.  Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.

Authors:  Yasushi Shimo; Thomas Wichmann
Journal:  Eur J Neurosci       Date:  2008-12-12       Impact factor: 3.386

5.  Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.

Authors:  Tatsuya Yamamoto; Tomoyuki Uchiyama; Yoshinori Higuchi; Masato Asahina; Shigeki Hirano; Yoshitaka Yamanaka; Satoshi Kuwabara
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

6.  Striatal Glutamate and GABA after High Frequency Subthalamic Stimulation in Parkinsonian Rat.

Authors:  Kyung Jin Lee; Insop Shim; Jae Hoon Sung; Jae Taek Hong; Il Sup Kim; Chul Bum Cho
Journal:  J Korean Neurosurg Soc       Date:  2017-03-01

7.  Effects of subthalamic deep brain stimulation on striatal metabolic connectivity in a rat hemiparkinsonian model.

Authors:  Nadine Apetz; Elena Kordys; Mascha Simon; Britta Mang; Markus Aswendt; Dirk Wiedermann; Bernd Neumaier; Alexander Drzezga; Lars Timmermann; Heike Endepols
Journal:  Dis Model Mech       Date:  2019-05-24       Impact factor: 5.758

8.  The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.

Authors:  Asier Aristieta; Garikoitz Azkona; Ainhoa Sagarduy; Cristina Miguelez; José Ángel Ruiz-Ortega; Rosario Sanchez-Pernaute; Luisa Ugedo
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

9.  Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.

Authors:  Sylviane Lortet; Emilie Lacombe; Nicolas Boulanger; Pascal Rihet; Catherine Nguyen; Lydia Kerkerian-Le Goff; Pascal Salin
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

Review 10.  Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's disease.

Authors:  Maria Vadalà; Annamaria Vallelunga; Lucia Palmieri; Beniamino Palmieri; Julio Cesar Morales-Medina; Tommaso Iannitti
Journal:  Behav Brain Funct       Date:  2015-09-07       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.